Navigation Links
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
Date:8/6/2013

WASHINGTON, Aug. 6, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Vanda also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Vanda, with net proceeds to be used for sales and marketing expenditures which may include commercial launch activities for tasimelteon for the treatment of Non-24-Hour Disorder following the receipt of regulatory approval, if any, research and development activities and other general corporate purposes.

Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as the joint book-running managers of the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on February 11, 2011. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained from the offices of Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020 or via telephone at (800) 542-0970 or the offices of Piper Jaffray & Co., by mail at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by e-mail at prospectus@pjc.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more information on Vanda, please visit www.vandapharma.com.  

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect Vanda's future operating results and financial position. Such statements, including, but not limited to, those regarding statements about Vanda's expectations regarding its fundraising efforts, including the closing of the public offering and the underwriter's exercise of its over-allotment option, involve known and unknown risks that relate to Vanda's future events or future financial performance and the actual results could differ materially from those discussed in this communication. Risks and uncertainties that may cause Vanda's actual results to differ materially from those discussed in this communication can be found in the "Risk Factors" section of Vanda's Form 10-K, Forms 10-Q and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and Vanda assumes no responsibility to update or revise any forward-looking statements contained in this communication to reflect events, trends or circumstances after the date of this communication.

Company Contact:

Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contact:

Laney Landsman
Assistant Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
2. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
3. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
4. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
5. Vanda Pharmaceuticals, Inc. Sued by Investor
6. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
7. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
8. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
9. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
10. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
11. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the ... Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that it ... Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany ...
(Date:4/24/2017)... ... ... The bar for just about everything—apparel, eyewear, cars and even phone cases—is ... and film stardom.(1) Not to be left out is that most desired of commodities, ... gamut from being encrusted with jewels and precious metals to, at the very least, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental ... 1,961 people during the April 22-23 event at the San Mateo Event Center. ... barriers to care, CDA Cares educates the public and policymakers about the importance of ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
Breaking Medicine News(10 mins):